Advice
Distribution License terminated in the UK
In January 2020, the distribution license for cenegermin (Oxervate) was been terminated in the UK.
Medicine details
- Medicine name:
- cenegermin (Oxervate)
- SMC ID:
- SMC2124
- Indication:
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
- Pharmaceutical company
- Dompe UK Ltd
- BNF chapter
- Eye
- Submission type
- Non submission
- Status
- Withdrawn
- Date advice published
- 08 October 2018
Additional notes
In January 2020 Dompé farmaceutici S.p.A confirmed that the distribution license for cenegermin (Oxervate) has been terminated in the UK. In line with SMC process the SMC advice has been removed from the website.